Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Pharma (IGC) over the last 14 years, with Q3 2025 value amounting to $333000.0.

  • Pharma's Other Accumulated Expenses fell 5806.05% to $333000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $333000.0, marking a year-over-year decrease of 5806.05%. This contributed to the annual value of $1.0 million for FY2025, which is 13937.95% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Other Accumulated Expenses is $333000.0, which was down 5806.05% from $401000.0 recorded in Q2 2025.
  • Over the past 5 years, Pharma's Other Accumulated Expenses peaked at $1.0 million during Q1 2025, and registered a low of $210000.0 during Q4 2023.
  • In the last 3 years, Pharma's Other Accumulated Expenses had a median value of $417000.0 in 2024 and averaged $516888.9.
  • In the last 5 years, Pharma's Other Accumulated Expenses surged by 24142.86% in 2024 and then crashed by 5806.05% in 2025.
  • Quarter analysis of 3 years shows Pharma's Other Accumulated Expenses stood at $210000.0 in 2023, then soared by 241.43% to $717000.0 in 2024, then tumbled by 53.56% to $333000.0 in 2025.
  • Its Other Accumulated Expenses stands at $333000.0 for Q3 2025, versus $401000.0 for Q2 2025 and $1.0 million for Q1 2025.